Recombinant Mouse Myelin-oligodendrocyte glycoprotein (Mog)

What is Recombinant Mouse Myelin-oligodendrocyte Glycoprotein (MOG)?

Recombinant Mouse MOG is a laboratory-produced version of the naturally occurring MOG protein found in mice. MOG is a 28 kDa single-pass transmembrane glycoprotein that belongs to the immunoglobulin (Ig) superfamily. The native mouse MOG protein consists of a 28 amino acid signal sequence, a 128 amino acid extracellular domain (ECD) containing an Ig-like domain, a 21 amino acid transmembrane domain, and a 69 amino acid cytosolic fragment .

MOG is expressed exclusively by oligodendrocytes in the central nervous system (CNS) and is localized to the outer layer of the myelin sheath and in the oligodendrocyte plasma membrane. It functions as an adhesion molecule and mediator of immune activation in the CNS .

How does MOG function in the central nervous system?

MOG is located on the outermost lamellae of the myelin sheath, making it accessible to antibody-mediated attack . Its expression in the brain can serve as a temporal biomarker for myelin development . While its exact physiological function remains under investigation, MOG is thought to function as an adhesion molecule as well as a mediator of immune activation in the CNS . The protein's structural features, including its Ig-like domain, contribute to its ability to form dimers at the cell surface, which may be important for its normal function .

What is the structural composition of recombinant MOG?

The crystal structure of MOG extracellular domain (MOGED) has been determined at 1.8 Å resolution . The structure reveals an immunoglobulin (Ig)-like fold typical of the Ig superfamily. Detailed crystallographic data shows:

The final refined model comprises residues 2-117, 215 water molecules, and two sulfate ions, with an R factor of 20.1% and an R free of 23.7% .

How is recombinant MOG used in multiple sclerosis research?

Recombinant MOG is primarily used to induce experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS) and related CNS demyelinating diseases such as MOG antibody-associated disease (MOGAD) . In vivo administration of exogenous MOG protein or peptide induces EAE in multiple animal species .

The MOG-induced EAE model is particularly valuable because it can produce different forms of the disease depending on the preparation:

• MOG peptide 35-55 induces primarily T cell-mediated EAE in C57BL/6 mice

• Full-length human MOG induces B cell-dependent EAE with demyelinating antibodies

• Different mouse strains recognize different MOG epitopes, allowing for varied experimental approaches

These models enable researchers to study disease mechanisms, test therapeutic interventions, and investigate both cellular and humoral aspects of autoimmune demyelination.

What are the critical differences between human and mouse MOG proteins?

Despite 90% amino acid sequence identity in their extracellular domains , human and mouse MOG proteins exhibit important functional differences in experimental settings:

• Immunization with human MOG in C57BL/6 mice produces B cell-dependent EAE, while rodent MOG typically produces B cell-independent disease

• Antibodies against human MOG can bind to glycosylated MOG in myelin and to live oligodendrocytes, whereas antibodies against rat MOG bind poorly to native MOG in myelin

• Pathogenic antibodies generated by immunization with human MOG can induce dramatic changes in oligodendrocyte morphology when cross-linked, while antibodies to rat MOG lack this property

These differences highlight the importance of carefully selecting the appropriate MOG species for specific research questions, particularly when studying B cell contributions to disease.

How do post-translational modifications affect MOG's encephalitogenic properties?

Post-translational modifications, particularly glycosylation, significantly affect MOG's encephalitogenic properties. Research findings indicate:

• Pathogenic anti-MOG antibodies bind specifically to glycosylated MOG, whereas non-pathogenic antibodies bind to both glycosylated and deglycosylated forms

• Only antibodies that recognize properly glycosylated MOG can bind to live oligodendrocytes and induce pathogenic effects

• Enzymatic deglycosylation of MOG in myelin allows binding of normally non-pathogenic antibodies

• Western blot analysis shows that pathogenic antibodies recognize glycosylated MOG at approximately 25 kDa, while exhibiting different binding patterns to recombinant and deglycosylated MOG

When producing recombinant MOG for research, the preservation of proper glycosylation may be critical for generating physiologically relevant antibody responses, especially for B cell-dependent EAE models.

What are the optimal methods for inducing EAE with recombinant MOG?

The optimal methods for inducing EAE with recombinant MOG vary depending on the research question:

• For T cell-mediated EAE:

  • MOG peptide 35-55 (25 mg) is commonly used in C57BL/6 mice

  • Complete Freund's adjuvant supplemented with Mycobacterium tuberculosis

  • Pertussis toxin administration on days 0 and 2

• For B cell-dependent EAE:

  • Full-length human MOG extracellular domain (typically amino acids 1-125)

  • Expression in systems that maintain proper protein folding and glycosylation

  • C57BL/6 mice are commonly used for this model

• For studies in SJL mice:

  • Truncated human recombinant MOG (amino acids 1-120) expressed in insect cells

  • This induces immune responses to the 1-30 and 81-110 regions

Recent advances in production methods have addressed previous limitations related to protein insolubility, allowing for more consistent and reproducible EAE induction .

How do anti-MOG antibodies induce demyelination at the molecular level?

Anti-MOG antibodies induce demyelination through several molecular mechanisms revealed through in vitro studies with cultured oligodendrocytes:

• When anti-MOG antibodies bind to MOG on oligodendrocyte surfaces and are cross-linked by secondary antibodies, MOG rapidly repartitions into detergent-insoluble microdomains characteristic of lipid rafts

• This repartitioning triggers changes in the phosphorylation status of at least 10 different proteins in oligodendrocytes

• These signaling changes culminate in dramatic alterations to oligodendrocyte cytoarchitecture, including retraction of oligodendrocyte processes that correlates with cytoskeletal destabilization

• The morphological changes likely compromise the oligodendrocyte's ability to maintain the myelin sheath, leading to demyelination

This molecular pathway provides a mechanistic link between antibody binding and demyelination observed in vivo, offering potential targets for therapeutic intervention in antibody-mediated demyelinating diseases.

What are the different epitopes of MOG recognized across mouse strains?

Different mouse strains recognize distinct epitopes of the MOG protein, which has important implications for experimental design:

In SJL mice, intravenous administration of MOG 91-110 peptide can effectively treat EAE induced by truncated human MOG, suggesting the therapeutic potential of epitope-specific tolerance induction .

The encephalitogenic B cell epitopes on human MOG recognized by C57BL/6 mice are distributed across multiple regions rather than concentrated in one specific area .

How can recombinant MOG preparations be optimized for specific research questions?

Optimizing recombinant MOG preparations depends on the specific research focus:

• For studying T cell mechanisms:

  • Synthetic MOG peptides (e.g., MOG 35-55) at high purity

  • May not require glycosylation or native conformation

• For studying B cell contributions and demyelinating antibodies:

  • Full extracellular domain of human MOG with proper folding

  • Expression systems that maintain glycosylation (insect cells, mammalian cells)

  • Carrier-free formulations may be preferred for certain applications

• For protein stability:

  • Lyophilized MOG can be reconstituted at specific concentrations (e.g., 100 μg/mL) in PBS

  • Avoid repeated freeze-thaw cycles and use a manual defrost freezer

• For advanced immunological studies:

  • Site-directed mutagenesis of specific residues (e.g., P42S) can alter pathogenicity

  • Deglycosylated variants can be used to study the role of glycosylation

Recent advances in production methods have improved yield and solubility of recombinant human MOG, potentially offering better options for researchers .

How can researchers differentiate between pathogenic and non-pathogenic anti-MOG antibodies?

Differentiating between pathogenic and non-pathogenic anti-MOG antibodies is crucial for understanding disease mechanisms. Research indicates several methodological approaches:

• Binding to live oligodendrocytes:

  • Pathogenic antibodies bind to MOG on live cultured oligodendrocytes

  • Non-pathogenic antibodies typically fail to bind or bind weakly

• Effect on oligodendrocyte morphology:

  • When cross-linked, pathogenic antibodies induce dramatic changes in oligodendrocyte morphology

  • Non-pathogenic antibodies do not induce these changes

• Western blot analysis:

  • Pathogenic antibodies bind strongly to glycosylated MOG in myelin

  • Non-pathogenic antibodies may bind to recombinant or deglycosylated MOG but bind poorly to native glycosylated MOG

• In vivo transfer:

  • Pathogenic antibodies exacerbate EAE when transferred to B cell-deficient mice primed with MOG

  • Non-pathogenic antibodies have minimal or no effect in this model

These assays provide reliable methods to assess the pathogenic potential of anti-MOG antibodies, which is critical for evaluating therapeutic approaches targeting the humoral immune response in demyelinating diseases.

How can MOG-induced models inform therapeutic strategies for MS and MOGAD?

MOG-induced EAE models have revealed several promising therapeutic strategies:

• Epitope-specific tolerance induction:

  • Intravenous administration of MOG 91-110 peptide effectively treats EAE in SJL mice immunized with truncated human MOG

  • This approach supports the potential for antigen-dependent treatments in MS

• Modulation of T cell differentiation:

  • ATRA-containing liposomal adjuvants can transdifferentiate Th17 cells to a Tr1-like phenotype

  • This approach may reduce pathogenic T cell responses while promoting regulatory mechanisms

• Targeting pathogenic antibody functions:

  • Understanding how antibodies induce MOG redistribution into lipid rafts provides potential targets for intervention

  • Disrupting the signaling pathways activated by antibody binding could prevent demyelination

• B cell-targeted therapies:

  • The B cell-dependent human MOG EAE model is valuable for testing B cell-depleting or modulating therapies

These findings support developing antigen-specific approaches for treating MS and MOGAD, potentially offering more selective immunomodulation with fewer side effects than current broad-spectrum therapies.

How do variations in MOG sequences across species affect translational research?

Sequence variations in MOG across species have important implications for translational research:

• Antibody cross-reactivity:

  • Human MOG-specific antibodies may recognize different epitopes than those recognized by antibodies against rodent MOG

  • This affects the interpretation of animal studies when translating to human disease

• T cell epitope recognition:

  • The 90% sequence identity between human and mouse MOG extracellular domains still allows for species-specific differences in T cell recognition

  • These differences may influence immunogenicity and therapeutic responses

• Model selection:

  • Human MOG-induced EAE in C57BL/6 mice provides a more translational model for studying MOG antibody-associated diseases in humans

  • This model better recapitulates the B cell and antibody contribution seen in many MS patients and in MOGAD

• Therapeutic development:

  • Therapies developed against specific MOG epitopes need to account for species differences

  • Humanized mouse models expressing human MOG may offer advantages for certain therapeutic approaches

Understanding these cross-species differences is essential for properly interpreting experimental results and designing translational studies with potential clinical applications.